MYC and ovarian cancer: Another well‐known driver of ovarian cancer, MYC, is amplified in approximately 50% of high‐grade serous ovarian cancer56; however, analysis of the GEPIA platform, using the TCGA and normal datasets did not identify MYC as significantly overexpressed, Figure 2H.